BioAge Labs, Inc. (BIOA) shareholders
Close on Nov 17, 2026Market cap $234.07MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Benjamin Horowitz Joint filing with Marc Andreessen (9.00%) | 3,233,170 | 9.00% | 13D (active) | Sep 27, 2024 |
| Bihua Chen Joint filing with Cormorant Asset Management, LP (6.51%) | 2,890,605 | 6.51% | 13G (passive) amendment | Mar 31, 2026 |
| Kristen Fortney | 2,704,736 | 7.20% | 13G (passive) amendment | Dec 31, 2025 |
| Cormorant Asset Management, LP Joint filing with Bihua Chen (5.38%) | 2,390,605 | 5.38% | 13G (passive) amendment | Jun 30, 2026 |
| Dr. James I. Healy (“Healy”) Joint filing with Sofinnova Venture Partners XI, L.P. (“SVP XI”) (6.50%), Sofinnova Management XI, L.P. (“SM XI LP”) (6.50%) and 2 more | 2,304,901 | 6.70% | 13D (active) | Sep 27, 2024 |
| BlackRock, Inc. | 2,236,460 | 5.03% | 13G (passive) | Mar 31, 2026 |
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (5.40%) | 1,937,123 | 5.40% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BIOA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| a16z Capital Management, L.L.C. | 3,233,170 | 7.04% | $79.24M | – | 0.56% |
| BlackRock, Inc. | 2,849,077 | 6.21% | $69.83M | +581,321 | 0.00% |
| Cormorant Asset Management, LP | 2,390,605 | 5.21% | $58.59M | −500,000 | 3.00% |
| Sofinnova Investments, Inc. | 2,293,788 | 5.00% | $56.22M | – | 2.91% |
| Jupiter Topco LLC | 2,144,633 | 4.67% | $52.60M | New | 0.02% |
| Octagon Capital Advisors LP | 1,748,000 | 3.81% | $42.84M | – | 3.85% |
| Ra Capital Management, L.P. | 1,671,648 | 3.64% | $40.97M | +21,000 | 0.36% |
| Mpm Bioimpact LLC | 1,667,661 | 3.63% | $40.87M | New | 2.49% |
| Vanguard Capital Management LLC | 1,544,214 | 3.36% | $37.85M | +189,308 | 0.00% |
| Polar Capital Holdings Plc | 1,072,344 | 2.34% | $26.28M | −60,296 | 0.06% |
| Braidwell LP | 1,033,129 | 2.25% | $25.32M | −167,458 | 0.94% |
| State Street Corp | 1,021,464 | 2.23% | $25.04M | +170,570 | 0.00% |
| Geode Capital Management, LLC | 1,004,264 | 2.19% | $24.62M | +254,998 | 0.00% |
| Sands Capital Ventures, LLC | 786,353 | 1.71% | $19.27M | – | 3.14% |
| Orbimed Advisors LLC | 752,153 | 1.64% | $18.44M | +40,342 | 0.34% |
| D. E. Shaw & Co., Inc. | 742,761 | 1.62% | $18.21M | +43,571 | 0.01% |
| Balyasny Asset Management L.P. | 702,858 | 1.53% | $17.23M | −624,687 | 0.02% |
| Pivotal bioVenture Partners Investment Advisor LLC | 653,374 | 1.42% | $16.01M | – | 5.20% |
| Cosmic Management, LLC | 501,833 | 1.09% | $12.30M | – | 3.22% |
| Stempoint Capital LP | 464,171 | 1.01% | $11.38M | −213,137 | 1.96% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 151 | 38M | 82.2% | 29 / 60 | 40 / 19 | 9M | 3M |
| Q1 2026 | 144 | 35M | 75.6% | 49 / 46 | 27 / 17 | 15M | 3M |
| Q4 2025 | 114 | 24M | 51.6% | 29 / 41 | 24 / 9 | 7M | 5M |
| Q3 2025 | 94 | 21M | 46.6% | 14 / 33 | 20 / 3 | 1M | 1M |
| Q2 2025 | 83 | 21M | 45.2% | 25 / 31 | 9 / 9 | 5M | 4M |
| Q1 2025 | 67 | 20M | 44.2% | 15 / 16 | 18 / 12 | 2M | 1M |
| Q4 2024 | 65 | 20M | 42.8% | 36 / 11 | 11 / 29 | 5M | 7M |
| Q3 2024 | 58 | 21M | 45.6% | 58 / 0 | 0 / 0 | 21M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
159 funds held BIOA in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BIOA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,140,593 | 2.49% | $27.96M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 915,623 | 1.99% | $22.44M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 385,004 | 0.84% | $3.48M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 367,975 | 0.80% | $9.02M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 296,801 | 0.65% | $7.27M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 262,153 | 0.57% | $6.43M | 1.50% | Jun 30, 2026 |
| iShares Biotechnology ETF | 223,345 | 0.49% | $5.47M | 0.06% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 201,860 | 0.44% | $1.82M | 0.04% | Jul 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 171,445 | 0.37% | $4.20M | 0.07% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 155,536 | 0.34% | $2.69M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 155,296 | 0.34% | $2.69M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 142,676 | 0.31% | $2.47M | 0.01% | May 31, 2026 |
| Franklin Biotechnology Discovery Fund | 135,049 | 0.29% | $1.22M | 0.11% | Jul 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 127,778 | 0.28% | $2.21M | 0.12% | May 31, 2026 |
| iShares Micro-Cap ETF | 118,122 | 0.26% | $2.90M | 0.19% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eric Morgen | Chief Operating Officer, Director | 67,225 | 0.15% | Feb 19, 2026 |
| Kristen Fortney | Chief Executive Officer, Director | 976,949 | 2.13% | Feb 19, 2026 |
| Shane Barton | Principal Accounting Officer | 4,290 | 0.01% | Jul 1, 2026 |
| Dov A. Goldstein Md | Chief Financial Officer | 36,575 | 0.08% | Apr 24, 2026 |
| Paul D. Rubin | Chief Medical Officer | 0 | – | Apr 3, 2026 |
| James Healy | Director | 2,304,901 | 5.02% | Jun 12, 2026 |
| Jean Pierre Garnier | Director | – | – | Jun 12, 2026 |
| Vijay Satyanand Pande | Director | 3,233,170 | 7.04% | Jun 12, 2026 |
| Patrick G. Enright | Director | 1,710,589 | 3.73% | Jun 12, 2026 |
| Michael H. Davidson | Director | – | – | Jun 12, 2026 |
| Rekha Hemrajani | Director | 3,000 | 0.01% | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Shane Barton Principal Accounting Officer | Jun 30, 2026 | Option exercise | +4,290 | $10.85 | $46.55K | 4,290 |
| Shane Barton Principal Accounting Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −20,216 | $25.19 | $509.24K | 0 |
| Shane Barton Principal Accounting Officer | Jun 30, 2026 | Option exercise | +7,861 | $4.38 | $34.43K | 20,216 |
| Shane Barton Principal Accounting Officer | Jun 30, 2026 | Option exercise | +4,065 | $4.30 | $17.48K | 12,355 |
| Shane Barton Principal Accounting Officer | Jun 30, 2026 | Option exercise | +4,000 | $8.39 | $33.56K | 8,290 |
| Shane Barton Principal Accounting Officer | Jun 29, 2026 | Option exercise | +9,301 | $10.85 | $100.92K | 11,933 |
| Shane Barton Principal Accounting Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −42,350 | $25.21 | $1.07M | 0 |
| Shane Barton Principal Accounting Officer | Jun 29, 2026 | Option exercise | +14,198 | $4.38 | $62.19K | 42,350 |
| Shane Barton Principal Accounting Officer | Jun 29, 2026 | Option exercise | +8,958 | $4.30 | $38.52K | 28,152 |
| Shane Barton Principal Accounting Officer | Jun 29, 2026 | Option exercise | +7,261 | $8.39 | $60.92K | 19,194 |
| Dov A. Goldstein Md Chief Financial Officer | Apr 23, 2026 | Option exercise | +3,542 | $4.38 | $15.51K | 36,575 |
| Paul D. Rubin Chief Medical Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −8,820 | $17.81 | $157.08K | 0 |
| Paul D. Rubin Chief Medical Officer | Apr 1, 2026 | Option exercise | +5,437 | $4.11 | $22.35K | 5,437 |
| Paul D. Rubin Chief Medical Officer | Apr 1, 2026 | Option exercise | +3,383 | $6.57 | $22.23K | 8,820 |
| Paul D. Rubin Chief Medical Officer | Mar 2, 2026 | Option exercise | +5,433 | $4.11 | $22.33K | 5,433 |
| Paul D. Rubin Chief Medical Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −7,433 | $20.30 | $150.89K | 0 |
| Paul D. Rubin Chief Medical Officer | Mar 2, 2026 | Option exercise | +2,000 | $6.57 | $13.14K | 7,433 |
| Dov A. Goldstein Md Chief Financial Officer | Mar 1, 2026 | Option exercise | +3,542 | $4.38 | $15.51K | 33,033 |
| Paul D. Rubin Chief Medical Officer | Feb 2, 2026 | Option exercise | +5,433 | $4.11 | $22.33K | 5,433 |
| Paul D. Rubin Chief Medical Officer | Feb 2, 2026 | Option exercise | +2,000 | $6.57 | $13.14K | 7,433 |
| Paul D. Rubin Chief Medical Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −7,433 | $18.75 | $139.37K | 0 |
| Dov A. Goldstein Md Chief Financial Officer | Feb 1, 2026 | Option exercise | +3,541 | $4.38 | $15.51K | 29,491 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 16, 2026 | Option exercise | +3,542 | $4.38 | $15.51K | 25,950 |
| Kristen Fortney Chief Executive Officer, Director | Jan 13, 2026 | Sale(10b5-1 plan) | −233,107 | $18.12 | $4.22M | 976,949 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 13, 2026 | Option exercise | +27,000 | $8.39 | $226.53K | 49,408 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 13, 2026 | Sale(10b5-1 plan) | −8,974 | $18.43 | $165.39K | 40,434 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 13, 2026 | Sale(10b5-1 plan) | −1,923 | $21.08 | $40.54K | 22,408 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 13, 2026 | Sale(10b5-1 plan) | −11,663 | $20.54 | $239.56K | 24,331 |
| Dov A. Goldstein Md Chief Financial Officer | Jan 13, 2026 | Sale(10b5-1 plan) | −4,440 | $19.45 | $86.36K | 35,994 |
| Paul D. Rubin Chief Medical Officer | Jan 2, 2026 | Option exercise | +5,433 | $4.11 | $22.33K | 5,433 |
| Paul D. Rubin Chief Medical Officer | Jan 2, 2026 | Option exercise | +2,000 | $6.57 | $13.14K | 7,433 |
| Paul D. Rubin Chief Medical Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −7,433 | $12.85 | $95.51K | 0 |
| Paul D. Rubin Chief Medical Officer | Dec 9, 2025 | Option exercise | +18,000 | $6.57 | $118.26K | 18,000 |
| Paul D. Rubin Chief Medical Officer | Dec 9, 2025 | Sale(10b5-1 plan) | −18,000 | $12.00 | $216.00K | 0 |
| Paul D. Rubin Chief Medical Officer | Dec 4, 2025 | Sale(10b5-1 plan) | −68,897 | $10.19 | $702.06K | 0 |
| Paul D. Rubin Chief Medical Officer | Dec 4, 2025 | Option exercise | +68,897 | $4.11 | $283.17K | 68,897 |
| Vijay Satyanand Pande Director | Oct 3, 2024 | Buy | +25,306 | $19.90 | $503.59K | 1,119,195 |
| Vijay Satyanand Pande Director | Oct 2, 2024 | Buy | +67,096 | $19.73 | $1.32M | 1,093,889 |
| Vijay Satyanand Pande Director | Oct 1, 2024 | Buy | +126,793 | $19.73 | $2.50M | 1,026,793 |
| Shane Barton Principal Accounting Officer | Sep 27, 2024 | Buy | +2,632 | $18.00 | $47.38K | 2,632 |
| Rekha Hemrajani Director | Sep 27, 2024 | Buy | +3,000 | $18.00 | $54.00K | 3,000 |
| Bihua Chen – | Sep 27, 2024 | Conversion | +1,179,529 | – | – | 1,179,529 |
| Bihua Chen – | Sep 27, 2024 | Buy | +450,000 | $18.00 | $8.10M | 1,629,529 |
| Patrick G. Enright Director | Sep 27, 2024 | Buy | +400,000 | $18.00 | $7.20M | 1,710,589 |
| Patrick G. Enright Director | Sep 27, 2024 | Conversion | +1,310,589 | – | – | 1,310,589 |
| Vijay Satyanand Pande Director | Sep 27, 2024 | Conversion | +655,294 | – | – | 655,294 |
| Vijay Satyanand Pande Director | Sep 27, 2024 | Conversion | +855,972 | – | – | 855,972 |
| Vijay Satyanand Pande Director | Sep 27, 2024 | Conversion | +413,100 | – | – | 1,269,072 |
| Vijay Satyanand Pande Director | Sep 27, 2024 | Buy | +900,000 | $18.00 | $16.20M | 900,000 |
| Vijay Satyanand Pande Director | Sep 27, 2024 | Conversion | +189,609 | – | – | 189,609 |
| James Healy Director | Sep 27, 2024 | Buy | +11,113 | $18.00 | $200.03K | 11,113 |
| James Healy Director | Sep 27, 2024 | Buy | +21,814 | $18.00 | $392.65K | 21,814 |
| James Healy Director | Sep 27, 2024 | Buy | +18,353 | $18.00 | $330.35K | 18,353 |
| James Healy Director | Sep 27, 2024 | Buy | +26,497 | $18.00 | $476.95K | 26,497 |
| James Healy Director | Sep 27, 2024 | Buy | +588,888 | $18.00 | $10.60M | 2,227,124 |
| James Healy Director | Sep 27, 2024 | Conversion | +1,638,236 | – | – | 1,638,236 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioAge Labs's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,800 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shane Barton Officer | Jun 30, 2026 | 20,216 | $509.18K | Jun 30, 2026 | Stock Option Exercise |
| Shane Barton Officer | Jun 29, 2026 | 42,350 | $1.07M | Jun 29, 2026 | IPO Shares |
| Paul D. Rubin Officer | Apr 1, 2026 | 8,820 | $157.08K | Apr 1, 2026 | Option Granted 07/01/2020 |
| Paul D. Rubin Officer | Mar 2, 2026 | 7,433 | $148.88K | Mar 2, 2026 | Option Granted 07/01/2020 |
| Paul D. Rubin Officer | Feb 2, 2026 | 7,433 | $139.37K | Feb 2, 2026 | Option Granted - 07/01/2020 |
| Kristen Fortney 10% Stockholder | Jan 13, 2026 | 233,107 | $4.20M | Jan 13, 2026 | RESTRICTED STOCK PURCHASE |
| Dov A. Goldstein Md Officer | Jan 13, 2026 | 27,000 | $531.83K | Jan 13, 2026 | Option Granted - 04/17/2024 |
| Paul D. Rubin Officer | Jan 2, 2026 | 7,433 | $99.68K | Jan 2, 2026 | Options Granted - 07/01/2020 |
| Paul D. Rubin Officer | Dec 9, 2025 | 18,000 | $216.00K | Dec 9, 2025 | Options Granted - 05/29/2022 |
| Paul D. Rubin Officer | Dec 4, 2025 | 68,897 | $701.91K | Dec 4, 2025 | Option Granted - 07/01/2020 |
Congress trades
4 trades in BioAge Labs reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Suzan K. DelBene WA01 · joint account | Sold | Jun 9, 2016 | $1K–15K | Jul 13, 2016 |
| Suzan K. DelBene WA01 · joint account | Bought | Oct 10, 2014 | $1K–15K | Nov 20, 2014 |
| Suzan K. DelBene WA01 · joint account | Bought | Oct 9, 2014 | $1K–15K | Nov 20, 2014 |
| Suzan K. DelBene WA01 · joint account | Bought | Jul 24, 2014 | $15K–50K | Aug 17, 2014 |
See a number that looks wrong?